Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Twist Bioscience Corp's President and COO, Patrick John Finn, reported a small mandatory share sale related to equity compensation. On 01/23/2026, he sold 2,390 shares of common stock at $44.908 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company's equity incentive plans and are described as non-discretionary trades. Following this transaction, he beneficially owned 310,493 shares of Twist Bioscience common stock directly.
An affiliate of TWST has filed a Rule 144 notice to sell 2,390 shares of common stock, with an aggregate market value of 107,329.41, through Fidelity Brokerage Services on NASDAQ around 01/23/2026.
These shares were acquired on 01/22/2026 via restricted stock vesting from the issuer as compensation. The filing also shows that Patrick Finn has sold multiple blocks of common stock over the past three months, including 23,279 shares on 01/13/2026 for gross proceeds of 931,160.00.
Twist Bioscience Corp’s Chief Financial Officer, Adam Laponis, reported a planned sale of company stock. On 01/13/2026, he sold 3,000 shares of Twist Bioscience common stock at a price of $40 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan that he adopted on May 8, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this sale, Laponis directly beneficially owned 137,031 shares of Twist Bioscience common stock.
Twist Bioscience Corp President and COO Patrick John Finn reported an option exercise and share sale in the company’s stock. On January 13, 2026, he exercised a stock option for 3,279 shares of common stock at an exercise price of $8.82 per share and acquired those shares directly.
On the same date, he sold 23,279 shares of Twist Bioscience common stock at a price of $40 per share in an open-market transaction. After these transactions, Finn directly owned 312,883 shares of common stock. The filing notes that these transactions were carried out under a previously adopted Rule 10b5-1 trading plan put in place on May 13, 2025.
Twist Bioscience Corp's Chief Financial Officer, Adam Laponis, reported an automatic sale of common stock to cover taxes related to equity compensation. On January 9, 2026, he sold 2,738 shares of common stock at a price of $35.261 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units under the company's equity incentive plans and were executed as mandatory "sell to cover" transactions rather than discretionary trades. After this sale, Laponis directly beneficially owned 140,031 shares of Twist Bioscience common stock.
An affiliate of TWST has filed a Form 144 notice for a proposed sale of 23,279 shares of common stock through Fidelity Brokerage Services LLC, to be sold on NASDAQ around 01/13/2026. The filing lists an aggregate market value of $931,160.00 and notes that 61,148,026 shares of this class were outstanding.
The shares to be sold were acquired mainly through restricted stock vesting, an employee stock purchase plan, and an option granted on 09/29/2017, with acquisition and payment dates between 02/18/2022 and 02/20/2025. The notice also reports that Patrick Finn sold additional common shares over the prior three months on dates including 10/23/2025 and 10/30/2025, with individual transactions such as 2,240 shares for $69,159.78 and 17,606 shares for $553,608.35.
Adam Laponis filed a Form 144 notice to sell 3,000 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of 120000.00. The securities to be sold were acquired via restricted stock vesting from the issuer on three dates: 267 shares on 10/29/2025, 784 shares on 11/20/2025, and 1,949 shares on 01/08/2026, all as compensation. The filing notes that 61,148,026 shares of this class were outstanding.
Over the prior three months, Adam Laponis sold additional common shares: 5,517 shares on 10/30/2025 for gross proceeds of 173,478.20, 887 shares on 11/21/2025 for 23,508.60, and 2,738 shares on 01/09/2026 for 96,544.34. The notice includes a representation that the seller is not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Twist Bioscience Corporation furnished a current report to share preliminary, unaudited revenue results for its first quarter of fiscal 2026, covering the period ended December 31, 2025. The company announced these early revenue figures in a press release dated January 12, 2026, which is included as Exhibit 99.1. Twist notes that these revenue expectations are preliminary and may change after it completes its internal control, review, and audit procedures, so the final numbers in its quarterly financial statements could differ materially. The company also states that this information is being furnished, not filed, which limits how it is treated under securities law.
Adam Laponis has filed a notice of proposed sale of common stock under Rule 144. The filing covers a planned sale of 2,738 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $96,544.34, when approximately 61,148,026 shares were outstanding and the shares are expected to be sold around 01/09/2026 on NASDAQ.
The 2,738 shares were acquired on 01/08/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, the same seller reported additional sales of common stock, including 2,517 shares for gross proceeds of $82,864.17, 5,517 shares for $173,478.20, and 887 shares for $23,508.60.
Twist Bioscience Corp (TWST) reported an insider transaction by its Senior Vice President, Chief Legal Officer & Corporate Secretary. On 11/21/2025, the reporting person sold 757 shares of Twist Bioscience common stock at a price of $26.5035 per share. After this transaction, the insider beneficially owned 145,402 shares directly.
The company explains that these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units. The sale was executed under the issuer’s equity incentive plan using a mandated “sell to cover” arrangement, meaning the transaction did not represent a discretionary trade or a change in the insider’s investment view.